LEGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

315.49M

+69.14%

-0.160

-214.46%

328.90M

+68.62%

-0.070

-87.04%

357.95M

+40.34%

-0.030

-95.59%

Estimates Revision

The market is revising Downward the revenue expectations for Legend Biotech Corporation (LEGN) for FY2025, with the revenue forecasts being adjusted by -0.99% over the past three months. During the same period, the stock price has changed by -25.55%.

Revenue Estimates for FY2025

Revise Downward

-0.99%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+61.58%

In Past 3 Month

Stock Price

Go Down

-25.55%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast LEGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEGN is 73.75 USD with a low forecast of 60.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

60.00

Averages

73.75

High

90.00

Current: 0.000

Low

60.00

Averages

73.75

High

90.00

Oppenheimer

Outperform

initiated

$75

2026-01-07

New

Reason

Oppenheimer

Price Target

$75

2026-01-07

New

initiated

Outperform

Reason

Oppenheimer initiated coverage of Legend Biotech with an Outperform rating and $75 price target. The firm notes the company commercializes Carvykti, a multiple-myeloma CAR-T therapy whose sales surpass all CARTs across all indications and are expected to deliver Legend profitability in 2026. Despite Carvykti's notable growth, Oppenheimer believes Legend is the most undervalued company among 11 relevant peers and trading near its all-time low price, largely due to market concerns around potential competition from Anito-cel and Dara-Tec. Acknowledging Anito-cel/Dara-Tec competitiveness, the firm thinks market concerns are overdone, and Legend risk/reward is significantly skewed to the upside.

Cantor Fitzgerald

Overweight

maintain

$75 -> $74

2025-12-17

Reason

Cantor Fitzgerald

Price Target

$75 -> $74

2025-12-17

maintain

Overweight

Reason

Cantor Fitzgerald lowered the firm's price target on Legend Biotech to $74 from $75 and keeps an Overweight rating on the shares. Despite heightened discussion around competition at ASH, Legend Biotech's management highlighted Carvykti's differentiation through long-term data, a broad label, and demonstrated survival benefit, the analyst tells investors in a research note. Management also emphasized the company's ability to scale production to meet rising real-time demand in the multiple myeloma market.

Morgan Stanley

Overweight -> NULL

downgrade

$83 -> $50

2025-12-12

Reason

Morgan Stanley

Price Target

$83 -> $50

2025-12-12

downgrade

Overweight -> NULL

Reason

Morgan Stanley lowered the firm's price target on Legend Biotech to $50 from $83 and keeps an Overweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

UBS

Ashwani Verma

Buy

downgrade

$54 -> $48

2025-12-08

Reason

UBS

Ashwani Verma

Price Target

$54 -> $48

2025-12-08

downgrade

Buy

Reason

UBS analyst Ashwani Verma lowered the firm's price target on Legend Biotech to $48 from $54 and keeps a Buy rating on the shares.

H.C. Wainwright

Mitchell Kapoor

Buy

maintain

$60

2025-11-26

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$60

2025-11-26

maintain

Buy

Reason

H.C. Wainwright analyst Mitchell Kapoor says private company Kelonia Therapeutics reported early in vivo CAR-T data that showed no detectable cancer cells in all three treated patients and "robust" CAR-T expansion without lymphodepletion. The data pressured valuations across the B-cell maturation antigen space, the analyst tells investors in a research note. However, H.C. Wainwright believes Kelonia's dataset remains "extremely small" and "far from" clinically comparable to a commercial-stage CAR-T. It sees little readthrough to Legend Biotech's Carvykti and reiterates a Buy rating on the shares with a $60 price target. Legend's competitive fears are overdone, the firm contends.

Cantor Fitzgerald

Overweight

maintain

$66 -> $75

2025-11-13

Reason

Cantor Fitzgerald

Price Target

$66 -> $75

2025-11-13

maintain

Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Legend Biotech to $75 from $66 and keeps an Overweight rating on the shares. Legend reported Q3 earnings, with sales for Carvykti reaching $524M in Q3, marking another record quarter for a CAR T-cell therapy, the analyst tells investors in a research note. The firm says the outlook for BCMA-directed CAR T therapy is robust, driven by earlier adoption, Carvykti's overall survival benefit, and broader outpatient and community adoption.

Valuation Metrics

The current forward P/E ratio for Legend Biotech Corp (LEGN.O) is -82.67, compared to its 5-year average forward P/E of -26.12. For a more detailed relative valuation and DCF analysis to assess Legend Biotech Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-26.12

Current PE

-82.67

Overvalued PE

86.67

Undervalued PE

-138.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-17.93

Current EV/EBITDA

28.96

Overvalued EV/EBITDA

10.56

Undervalued EV/EBITDA

-46.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

28.04

Current PS

2.87

Overvalued PS

49.79

Undervalued PS

6.30

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LEGN News & Events

Events Timeline

No data

News

8.0

2025-12-19NASDAQ.COM

Initial Week of LEGN Options Trading for August 2026

1.0

2025-12-17Globenewswire

Legend Biotech CEO to Present Latest Updates at J.P. Morgan Conference

3.0

2025-12-11MarketWatch

Eight Stock Selections to Capitalize on a Robust Sector of the Market

People Also Watch

Frequently Asked Questions

What is Legend Biotech Corp (LEGN) stock price today?

The current price of LEGN is 23.6 USD — it has increased 2.48 % in the last trading day.

What is Legend Biotech Corp (LEGN)'s business?

Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

What is the price predicton of LEGN Stock?

What is Legend Biotech Corp (LEGN)'s revenue for the last quarter?

Legend Biotech Corp revenue for the last quarter amounts to 272.33M USD, increased 69.99 % YoY.

What is Legend Biotech Corp (LEGN)'s earnings per share (EPS) for the last quarter?

Legend Biotech Corp. EPS for the last quarter amounts to -0.11 USD, decreased -67.65 % YoY.

What changes have occurred in the market's expectations for Legend Biotech Corp (LEGN)'s fundamentals?

How many employees does Legend Biotech Corp (LEGN). have?

Legend Biotech Corp (LEGN) has 2600 emplpoyees as of January 10 2026.

What is Legend Biotech Corp (LEGN) market cap?

Today LEGN has the market capitalization of 4.36B USD.